Central GLP-1 Actions on Energy Metabolism

Vitamins and Hormones

Volumn 84, Issue C, 2010, Pages 303-317

  Velásquez, Douglas A ^a,b   Beiroa, Daniel ^a,b   Vázquez, María J ^a,b   Romero, Amparo ^a,b   López, Miguel ^a,b   Diéguez, Carlos ^a,b   Nogueiras, Ruben ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ANIMAL; BOOK; CENTRAL NERVOUS SYSTEM; EATING; ENERGY METABOLISM; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 2; EATING; ENERGY METABOLISM; FATTY ACIDS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS;

EID: 78649378017     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381517-0.00011-4     Document Type: Book

References (76)

1. Alvarez E., Martinez M.D., Roncero I., Chowen J.A., Garcia-Cuartero B., Gispert J.D., Sanz C., Vazquez P., Maldonado A., de Caceres J., Desco M., Pozo M.A., et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 2005, 92:798-806.
2. Astrup A., Rossner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M.F., Lean M.E. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
3. Badman M.K., Flier J.S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007, 132:2103-2115.
4. Barragan J.M., Eng J., Rodriguez R., Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am. J. Physiol. 1999, 277:E784-E791.
5. Barrera J.G., D'Alessio D.A., Drucker D.J., Woods S.C., Seeley R.J. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 2009, 58:2820-2827.
6. Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Penicaud L., Drucker D.J., Magnan C., Burcelin R. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008, 57:2577-2587.
7. D'Alessio D.A., Sandoval D.A., Seeley R.J. New ways in which GLP-1 can regulate glucose homeostasis. J. Clin. Invest. 2005, 115:3406-3408.
8. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., Findeisen H., Bruemmer D., Drucker D.J., Chaudhary N., Holland J., Hembree J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 2009, 5:749-757.
9. Delgado-Aros S., Kim D.Y., Burton D.D., Thomforde G.M., Stephens D., Brinkmann B.H., Vella A., Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G424-G431.
10. Djurhuus C.B., Hansen T.K., Gravholt C., Orskov L., Hosoda H., Kangawa K., Jorgensen J.O., Holst J.J., Schmitz O. Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm. Metab. Res. 2002, 34:411-413.
11. Drucker D.J. Glucagon-like Peptide 2. Trends Endocrinol. Metab. 1999, 10:153-156.
12. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
13. Drucker D.J. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 2007, 117:24-32.
14. Goke R., Fehmann H.C., Goke B. Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate. Eur. J. Clin. Invest. 1991, 21:135-144.
15. Goldstone A.P., Morgan I., Mercer J.G., Morgan D.G., Moar K.M., Ghatei M.A., Bloom S.R. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem. Biophys. Res. Commun. 2000, 269:331-335.
16. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., Winterhalder R., Conen D., Beglinger C. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999, 44:81-86.
17. Gutzwiller J.P., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J., Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 1999, 276:R1541-R1544.
18. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87:1409-1439.
19. Holst J.J., Orskov C. The incretin approach for diabetes treatment: Modulation of islet hormone release by GLP-1 agonism. Diabetes 2004, 53(Suppl 3):S197-S204.
20. Hwa J.J., Ghibaudi L., Williams P., Witten M.B., Tedesco R., Strader C.D. Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 1998, 19:869-875.
21. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am. J. Physiol. 1997, 273:G920-G927.
22. Jeppesen P.B. Clinical significance of GLP-2 in short-bowel syndrome. J. Nutr. 2003, 133:3721-3724.
23. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
24. Kinzig K.P., D'Alessio D.A., Seeley R.J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J. Neurosci. 2002, 22:10470-10476.
25. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., Benhamed F., Gremeaux T., Drucker D.J., Kahn C.R., Girard J., Tanti J.F., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest. 2005, 115:3554-3563.
26. Knauf C., Cani P.D., Ait-Belgnaoui A., Benani A., Dray C., Cabou C., Colom A., Uldry M., Rastrelli S., Sabatier E., Godet N., Waget A., et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008, 149:4768-4777.
27. Knauf C., Cani P.D., Kim D.H., Iglesias M.A., Chabo C., Waget A., Colom A., Rastrelli S., Delzenne N.M., Drucker D.J., Seeley R.J., Burcelin R. Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes 2008, 57:2603-2612.
28. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987, 2:1300-1304.
29. Lachey J.L., D'Alessio D.A., Rinaman L., Elmquist J.K., Drucker D.J., Seeley R.J. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: Differential effects in rats and mice. Endocrinology 2005, 146:458-462.
30. Lam T.K., Pocai A., Gutierrez-Juarez R., Obici S., Bryan J., Aguilar-Bryan L., Schwartz G.J., Rossetti L. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat. Med. 2005, 11:320-327.
31. Larsen P.J., Tang-Christensen M., Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455.
32. Lippl F., Kircher F., Erdmann J., Allescher H.D., Schusdziarra V. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regul. Pept. 2004, 119:93-98.
33. McMahon L.R., Wellman P.J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 1998, 274:R23-R29.
34. Meeran K., O'Shea D., Edwards C.M., Turton M.D., Heath M.M., Gunn I., Abusnana S., Rossi M., Small C.J., Goldstone A.P., Taylor G.M., Sunter D., et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999, 140:244-250.
35. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 1999, 403:261-280.
36. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79:616-619.
37. Munroe D.G., Gupta A.K., Kooshesh F., Vyas T.B., Rizkalla G., Wang H., Demchyshyn L., Yang Z.J., Kamboj R.K., Chen H., McCallum K., Sumner-Smith M., et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 1999, 96:1569-1573.
38. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
39. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., Rossner S., Hellstrom P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord. 1999, 23:304-311.
40. Nogueiras R., Perez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G., Patterson J.T., Disse E., Pfluger P.T., Lopez M., Woods S.C., DiMarchi R., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci. 2009, 29:5916-5925.
41. Obici S., Zhang B.B., Karkanias G., Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 2002, 8:1376-1382.
42. Obici S., Feng Z., Arduini A., Conti R., Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat. Med. 2003, 9:756-761.
43. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
44. Perez-Tilve D., Gonzalez-Matias L., Alvarez-Crespo M., Leiras R., Tovar S., Dieguez C., Mallo F. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007, 56:143-151.
45. Plum L., Belgardt B.F., Bruning J.C. Central insulin action in energy and glucose homeostasis. J. Clin. Invest. 2006, 116:1761-1766.
46. Pocai A., Lam T.K., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., Aguilar-Bryan L., Rossetti L. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 2005, 434:1026-1031.
47. Raun K., von Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
48. Riediger T., Eisele N., Scheel C., Lutz T.A. Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298:R1061-R1067.
49. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am. J. Physiol. 1999, 277:R1537-R1540.
50. Roberge J.N., Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993, 133:233-240.
51. Rodriquez de Fonseca F., Navarro M., Alvarez E., Roncero I., Chowen J.A., Maestre O., Gomez R., Munoz R.M., Eng J., Blazquez E. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000, 49:709-717.
52. Sandoval D. CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol. Behav. 2008, 94:670-674.
53. Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., Seeley R.J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008, 57:2046-2054.
54. Schmidt P.T., Naslund E., Gryback P., Jacobsson H., Hartmann B., Holst J.J., Hellstrom P.M. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul. Pept. 2003, 116:21-25.
55. Scott R.B., Kirk D., MacNaughton W.K., Meddings J.B. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. 1998, 275:G911-G921.
56. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 1996, 2:1254-1258.
57. Seo S., Ju S., Chung H., Lee D., Park S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr. J. 2008, 55:867-874.
58. Shimizu I., Hirota M., Ohboshi C., Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987, 121:1076-1082.
59. Sorensen L.B., Flint A., Raben A., Hartmann B., Holst J.J., Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int. J. Obes. Relat. Metab. Disord. 2003, 27:450-456.
60. Tang-Christensen M., Larsen P.J., Goke R., Fink-Jensen A., Jessop D.S., Moller M., Sheikh S.P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 1996, 271:R848-R856.
61. Tang-Christensen M., Vrang N., Larsen P.J. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998, 47:530-537.
62. Tang-Christensen M., Larsen P.J., Thulesen J., Romer J., Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat. Med. 2000, 6:802-807.
63. Thiele T.E., Van Dijk G., Campfield L.A., Smith F.J., Burn P., Woods S.C., Bernstein I.L., Seeley R.J. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am. J. Physiol. 1997, 272:R726-R730.
64. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143.
65. Tsai C.H., Hill M., Drucker D.J. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am. J. Physiol. 1997, 272:G662-G668.
66. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
67. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
68. Ulrich-Lai Y.M., Herman J.P. Neural regulation of endocrine and autonomic stress responses. Nat. Rev. Neurosci. 2009, 10:397-409.
69. Uttenthal L.O., Toledano A., Blazquez E. Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 1992, 21:143-146.
70. van Dijk G., Thiele T.E., Seeley R.J., Woods S.C., Bernstein I.L. Glucagon-like peptide-1 and satiety. Nature 1997, 385:214.
71. Wang Q., Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002, 45:1263-1273.
72. Wang Z., Wang R.M., Owji A.A., Smith D.M., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 is a physiological incretin in rat. J. Clin. Invest. 1995, 95:417-421.
73. Wettergren A., Wojdemann M., Holst J.J. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am. J. Physiol. 1998, 275:G984-G992.
74. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
75. Wojdemann M., Wettergren A., Hartmann B., Holst J.J. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand. J. Gastroenterol. 1998, 33:828-832.
76. Wojdemann M., Wettergren A., Hartmann B., Hilsted L., Holst J.J. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J. Clin. Endocrinol. Metab. 1999, 84:2513-2517.